NIH R01 · 2024
Hepatoprotective Mechanisms of Systemic Bile Acid Transporter Inhibitors
The overarching goal of this application is to advance our understanding of the role of the Apical sodium- dependent bile acid (BA) transporter (ASBT; also called IBAT) in the pathogenesis of cholestatic liver disease and associated kidney injury, and to elucidate the therapeutic mechanisms of action of systemically acting ASBT inhibitors. In addition to ileal enterocytes, ASBT is expressed by kidney proximal tubule epithelial cells to limit BA loss in urine. ASBT is also expressed by cholangiocytes in the liver, where ASBT can mediate cholehepatic shunting of BAs. In contrast to ileum, much less is known regarding the ASBT’s role in those tissue compartments in cholestatic liver disease or…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.